Michael Atkin

Michael Atkin serves as the CEO of Synergy Therapeutics Inc., focusing on innovative approaches for targeting p53 in oncology since March 2023. Michael also holds the position of Director at Syzent Partners LLC and has been a Board Member at Affinité Instruments since January 2016, where efforts are directed toward developing label-free detection methods for precision diagnostics. Michael Atkin has mentored industry teams at Rutgers University and Princeton University, guiding them through technology development and market validation. Previous roles include General Manager at NMX Research and Solutions Inc., Chairman of the Board at Ortho RTI, and President & CEO of Gladius Pharmaceuticals Inc., contributing to advancements in drug development and life sciences consulting. Educational credentials include an MBA in Finance from Columbia Business School and a BA (Hons.) from the University of Kent.